Fat Mass and Survival in Immunotherapy-Treated Metastatic Renal Cell Carcinoma Patients.

IF 1.9 3区医学 Q3 ONCOLOGY

Oncology Pub Date : 2026-07-16 DOI:10.1159/000552741

Tanguy Bouget, Marine Lottin, Abeer Najem, Sahir Javed, Marine Marrucho, Julien Elices-Diez, Pierre-Yves Cren, Marie-Cécile Le Deley, Nicolas Penel, Aurélien Carnot, Gautier Marcq, Alexandra Forestier

{"title":"Fat Mass and Survival in Immunotherapy-Treated Metastatic Renal Cell Carcinoma Patients.","authors":"Tanguy Bouget, Marine Lottin, Abeer Najem, Sahir Javed, Marine Marrucho, Julien Elices-Diez, Pierre-Yves Cren, Marie-Cécile Le Deley, Nicolas Penel, Aurélien Carnot, Gautier Marcq, Alexandra Forestier","doi":"10.1159/000552741","DOIUrl":null,"url":null,"abstract":"Introduction: Immune checkpoint inhibitors (ICIs) are widely prescribed as the first-line treatment for metastatic renal clear-cell carcinoma because of their overall survival (OS) benefits. However, ICIs are associated with unreliable efficacy and sometimes severe and unpredictable toxicities. There is a lack of biomarkers for efficacy or toxicity beyond the IMDC score. Body composition (fat and muscle mass) may also be a biomarker of interest. The aim of this retrospective study was to analyze the association between body composition, OS, and toxicities in patients with RCC treated with ICI as a first-line metastatic treatment.Methods: Body composition parameters - subcutaneous fat index (SFI), visceral fat index (VFI), total fat index (TFI), and skeletal muscle index (SMI) - were measured on computed tomography scans using semiautomated software.Results: In 71 patients, no significant association was found between TFI and OS (adjusted HR, 0.71 [0.35; 1.45]) or toxicities. The TFI was strongly correlated with BMI (r = 0.81), whereas the SFI and VFI were weakly correlated.Conclusion: Larger studies would be valuable to better define the thresholds of different parameters (SFI, VFI, TFI, and SMI) and their association with the efficacy and toxicity of ICI.","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"1-12"},"PeriodicalIF":1.9000,"publicationDate":"2026-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000552741","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Immune checkpoint inhibitors (ICIs) are widely prescribed as the first-line treatment for metastatic renal clear-cell carcinoma because of their overall survival (OS) benefits. However, ICIs are associated with unreliable efficacy and sometimes severe and unpredictable toxicities. There is a lack of biomarkers for efficacy or toxicity beyond the IMDC score. Body composition (fat and muscle mass) may also be a biomarker of interest. The aim of this retrospective study was to analyze the association between body composition, OS, and toxicities in patients with RCC treated with ICI as a first-line metastatic treatment.

Methods: Body composition parameters - subcutaneous fat index (SFI), visceral fat index (VFI), total fat index (TFI), and skeletal muscle index (SMI) - were measured on computed tomography scans using semiautomated software.

Results: In 71 patients, no significant association was found between TFI and OS (adjusted HR, 0.71 [0.35; 1.45]) or toxicities. The TFI was strongly correlated with BMI (r = 0.81), whereas the SFI and VFI were weakly correlated.

Conclusion: Larger studies would be valuable to better define the thresholds of different parameters (SFI, VFI, TFI, and SMI) and their association with the efficacy and toxicity of ICI.

查看原文本刊更多论文

免疫治疗转移性肾细胞癌患者的脂肪量和生存率。

免疫检查点抑制剂（ICI）被广泛用作转移性肾透明细胞癌（mRCC）的一线治疗，因为它们的总体生存期改善。然而，ICI的疗效不可靠，有时还伴有严重和不可预测的毒性。在IMDC评分之外，缺乏疗效或毒性的生物标志物。身体成分（脂肪和肌肉质量）也可能是一个感兴趣的生物标志物。本回顾性研究的目的是分析以ICI作为一线转移性治疗的RCC患者的身体组成、总生存期（OS）和毒性之间的关系。方法：使用半自动软件在计算机断层扫描上测量身体组成参数——皮下脂肪指数（SFI）、内脏脂肪指数（VFI）、总脂肪指数（TFI）和骨骼肌指数（SMI）。结果：71例患者中，TFI与OS（调整HR 0.70, 95% CI =[0.33-1.48]）或毒性之间无显著关联。TFI与BMI呈强相关（r=0.81）， SFI与VFI呈弱相关。结论：更大规模的研究将有助于更好地定义不同参数（SFI、VFI、TFI和SMI）的阈值及其与ICI疗效和毒性的关系。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncology 医学-肿瘤学

CiteScore

6.00

自引率

2.90%

发文量

审稿时长

6-12 weeks

期刊介绍： Although laboratory and clinical cancer research need to be closely linked, observations at the basic level often remain removed from medical applications. This journal works to accelerate the translation of experimental results into the clinic, and back again into the laboratory for further investigation. The fundamental purpose of this effort is to advance clinically-relevant knowledge of cancer, and improve the outcome of prevention, diagnosis and treatment of malignant disease. The journal publishes significant clinical studies from cancer programs around the world, along with important translational laboratory findings, mini-reviews (invited and submitted) and in-depth discussions of evolving and controversial topics in the oncology arena. A unique feature of the journal is a new section which focuses on rapid peer-review and subsequent publication of short reports of phase 1 and phase 2 clinical cancer trials, with a goal of insuring that high-quality clinical cancer research quickly enters the public domain, regardless of the trial’s ultimate conclusions regarding efficacy or toxicity.